In a lung mouse cancer model, an approved clinical chemotherapy regimen (Oxaliplatin plus cyclophosphamide) were able to foster CD8+ T cell infiltration and increase TLR4+ DCs in tumor tissue, which leads to sensitization of tumors to immune checkpoint therapy (Pfirschke et al., 2016). This evidence concerns the gene CD8A and neoplasm.